Skip to content

Potential effect of proton-pump inhibitor on angiogenic markers in preeclampsia

Potential effect of proton-pump inhibitor on angiogenic markers in preeclampsia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON22488
Enrollment
44
Registered
2019-05-07
Start date
2018-12-17
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preeclampsia

Interventions

Omeprazole 40mg once daily

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Women (=18 years) with a singleton pregnancy diagnosed with PE with a gestational age of = 20 weeks and <35 weeks admitted to the obstetric department who give written informed consent, will be included.

Exclusion criteria

Exclusion criteria: - Multiple pregnancies - Not willing to give written informed consent. - Other reasons than (suspected) PE requiring hospitalization - The use of PPI at time of randomization - Contraindications or hypersensitivity to PPI use - The use of medication affected by PPI - Fetal death at time of inclusion - Signs of fetal distress at time of inclusion - Expected delivery of = 2 days

Design outcomes

Primary

MeasureTime frame
The difference in sFlt-1 levels in women who have received PPI, in comparison to women who have not received PPI.

Secondary

MeasureTime frame
The difference in other biomarkers such as PlGF, ET-1, sEndoglin, CT-proET-1 in women who have received PPI, in comparison to women who have not received PPI

Contacts

Public ContactRugina Neuman

Erasmus Medical Center

r.neuman@erasmusmc.nl0681469399

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)